Overview

Companies developing cell therapies choose to partner with MaxCyte based upon its ability to create therapeutics that cannot otherwise be developed. MaxCyte provides these partners with the ability to effectively manipulate cell function with a process that provides safety, reproducibility/consistency and scalability in a closed, cGMP process. In addition, the Company's existing FDA Master File and NIH RAC and Health Canada clearances allow partners to achieve rapid protocol approval and regulatory clearance. Each of these elements is required in the production of the cell therapy product in order to create a commercializable therapy. Limited by one or more of these elements, the Company's licensees have partnered with MaxCyte to move their programs forward.